NavonTech

Company Overview

Snapshot

Founded in December 2017 by Shai Feinsod, Shy Hefetz, and Yaniv Shtalryd, NavonTech operates with 1–10 employees. The company is currently in the Pre-Funding stage and holds one patent. NavonTech ceased operations in July 2022.

Business overview

NavonTech develops the GlycemiaCare watch, a wrist-worn, web-connected device designed for non-invasive monitoring of multiple physiological parameters to provide early warnings for nocturnal hypoglycemia. The technology monitors changes in heart rate, breathing rate, skin humidity, skin temperature, muscle twitches, and skin conductivity. The device features local alarms and vibrations to alert the wearer and can notify a predefined call list via Wi-Fi, Bluetooth, and a dedicated app, with an option to subscribe to a medical response center. Its machine-learning algorithm, developed through clinical trials, aims to minimize false alarms while maximizing detection rates. NavonTech operates in the Health Tech & Life Sciences sector, specifically within Digital Healthcare and Patient Remote Monitoring, serving patients and providers globally with a B2B2C and B2B business model.

Company Intelligence Q&A

What is NavonTech's primary product?

NavonTech's primary product is the GlycemiaCare watch, a wrist-worn device designed for non-invasive monitoring of physiological parameters to detect and warn of nocturnal hypoglycemia.

When was NavonTech founded?

NavonTech was founded in December 2017.

What is the operational status of NavonTech?

NavonTech ceased to operate in July 2022.

Who are the founders of NavonTech?

NavonTech was founded by Shai Feinsod, Shy Hefetz, and Yaniv Shtalryd.

What technology does the GlycemiaCare watch utilize?

The GlycemiaCare watch uses machine-learning technology based on clinical trials to analyze multiple physiological parameters for hypoglycemia detection, including heart rate, breathing rate, skin humidity, skin temperature, muscle twitches, and skin conductivity.